文献速递神经外科与老年麻醉

阻断Kv1.3钾通道可预防小鼠术后神经炎症与认知减退且不影响伤口愈合

Blocking Kv1.3 potassium channels prevents postoperative neuroinflammation and cognitive decline without impairing wound healing in mice.
PubMed 文献 · Br J Anaesth · 2020-07-02

该研究利用Kv1.3基因敲除小鼠和饮食诱导肥胖(DIO)小鼠模型,探讨电压门控钾通道Kv1.3在术后认知减退(PCD)中的作用。结果显示Kv1.3缺失小鼠术后恐惧冻结行为未改变;在DIO小鼠中,PAP-1阻断Kv1.3可预防术后冻结行为减弱、海马小胶质细胞激活和IL-6上调,且不影响血浆IL-6升高及骨折愈合。

要点

  • Kv1.3活性是小胶质细胞介导PCD所必需。
  • PAP-1阻断Kv1.3可预防DIO小鼠术后海马神经炎症和认知减退。
  • PAP-1不影响术后外周炎症及胫骨骨折愈合。

核心结论

  • 小胶质细胞介导的PCD需要Kv1.3活性,PAP-1阻断Kv1.3可预防PCD易感小鼠的术后海马小胶质细胞激活和神经炎症,且不影响骨折愈合。

研究设计与样本

  • 研究经机构批准,评估Kv1.3-/-小鼠是否表现出胫骨骨折手术诱导的厌恶冻结行为下降所代表的PCD,并评估PAP-1能否预防PCD易感DIO小鼠的PCD和术后神经炎症,同时评估PAP-1对术后外周炎症或胫骨骨折愈合的影响。

主要发现

  • 术后Kv1.3-/-小鼠冻结行为未改变。
  • DIO小鼠中,PAP-1预防术后冻结行为减弱(54 [17.3]% vs 33.4 [12.7]%;P=0.03)。
  • PAP-1预防海马小胶质细胞按大小(130 [31] pixels vs 249 [49];P<0.001)和荧光强度(12 000 [2260] vs 20 800 [5080] absorbance units;P<0.001)的激活。
  • PAP-1预防海马白细胞介素-6(IL-6)上调(14.9 [5.7] vs 25.6 [10.4] pg mg-1;P=0.011)。
  • PAP-1不影响手术诱导的血浆IL-6上调,也不影响手术骨折骨痂的软骨和骨成分。

临床怎么用

  • Kv1.3阻断剂(目前正在其他疾病中进行临床试验)可能代表一种有效且安全的预防PCD的干预措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative cognitive decline (PCD) requires microglial activation. Voltage-gated Kv1.3 potassium channels are involved in microglial activation. We determined the role of Kv1.3 in PCD and the efficacy and safety of inhibiting Kv1.3 with phenoxyalkoxypsoralen-1 (PAP-1) in preventing PCD in a mouse model. METHODS: After institutional approval, we assessed whether Kv1.3-deficient mice (Kv1.3-/-) exhibited PCD, evidenced by tibial-fracture surgery-induced decline in aversive freezing behaviour, and whether PAP-1 could prevent PCD and postoperative neuroinflammation in PCD-vulnerable diet-induced obese (DIO) mice. We also evaluated whether PAP-1 altered either postoperative peripheral inflammation or tibial-fracture healing. RESULTS: Freezing behaviour was unaltered in postoperative Kv1.3-/- mice. In DIO mice, PAP-1 prevented postoperative (i) attenuation of freezing behaviour (54 [17.3]% vs 33.4 [12.7]%; P=0.03), (ii) hippocampal microglial activation by size (130 [31] pixels vs 249 [49]; P<0.001) and fluorescence intensity (12 000 [2260] vs 20 800 [5080] absorbance units; P<0.001), and (iii) hippocampal upregulation of interleukin-6 (IL-6) (14.9 [5.7] vs 25.6 [10.4] pg mg-1; P=0.011). Phenoxyalkoxypsoralen-1 neither affected surgery-induced upregulation of plasma IL-6 nor cartilage and bone components of the surgical fracture callus. CONCLUSIONS: Microglial-mediated PCD requires Kv1.3 activity, determined by genetic and pharmacological targeting approaches. Phenoxyalkoxypsoralen-1 blockade of Kv1.3 prevented surgery-induced hippocampal microglial activation and neuroinflammation in mice known to be vulnerable to PCD. Regarding perioperative safety, these beneficial effects of PAP-1 treatment occurred without impacting fracture healing. Kv1.3 blockers, currently undergoing clinical trials for other conditions, may represent an effective and safe intervention to prevent PCD.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Lai IK, Valdearcos M, Morioka K, et al. Blocking Kv1.3 potassium channels prevents postoperative neuroinflammation and cognitive decline without impairing wound healing in mice. Br J Anaesth. 2020. PMID: 32624183. doi:10.1016/j.bja.2020.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。